Avilar

Curated by Signal

Provider of drug discovery platform and protein degradation technology

Overview

Provider of drug discovery platform and protein degradation technology. The company has built a proprietary technology platform to develop novel extracellular protein degraders called ATACs that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. It provides applications in a broad range of diseases.

Key facts

Founded: 2020
Headquarters: Waltham, United States
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

1 product or service: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Active Motif
Provider of research kits, assays and biocomputing systems
Life Sciences TechnologyCarlsbad, United States
NextBio
NextBio provides a platform to aggregate and interpret large quantities of genomic data for research and clinical applications.
Life Sciences TechnologySanta Clara, United States
NuEyes
Provider of visual magnification aid for blind and sight-impaired people
Life Sciences TechnologyNewport Beach, United States

About Avilar

What does Avilar do?

Provider of drug discovery platform and protein degradation technology.

Where is Avilar headquartered?

Avilar is headquartered in Waltham, United States.

When was Avilar founded?

Avilar was founded in 2020.

Which sector is Avilar in?

Avilar operates in Life Sciences Technology.

Who are Avilar's competitors?

Companies similar to Avilar include Active Motif, NextBio, and NuEyes.